Clinical trial results show promise of targeting autophagy BRAF mutant melanoma

Macroautophagy/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers. Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations. Here we highlight the results of a recent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Autophagy 2022-06, Vol.18 (6), p.1470-1471
1. Verfasser:	Amaravadi, Ravi K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autophagic Punctum Autophagy Autophagy - genetics clinical trial Humans hydroxychloroquine Hydroxychloroquine - pharmacology Hydroxychloroquine - therapeutic use melanoma Melanoma - drug therapy Melanoma - genetics Mutation - genetics Proto-Oncogene Proteins B-raf - genetics Pyrimidinones - adverse effects Skin Neoplasms - drug therapy targeted therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!